Ascendis Pharma A (ASND) Profit After Tax (2014 - 2026)

Ascendis Pharma A (ASND) has 13 years of Profit After Tax data on file, last reported at $736.8 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax rose 840.23% year-over-year to $736.8 million; the trailing twelve-month figure through Mar 2026 stood at $582.4 million (up 541.93% YoY), and the FY2025 full-year result was -$265.4 million, up 35.13% from the prior year.
• Profit After Tax advanced to $736.8 million in Q1 2026, from -$39.1 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $736.8 million in Q1 2026 to a low of -$209.4 million in Q4 2022.
• A 5-year average of -$48.4 million and a median of -$99.5 million in 2025 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax tumbled 2926722.79% in 2022 and jumped 840.23% in 2026, its largest moves.
• Tracing ASND's Profit After Tax over 5 years: stood at -$209.4 million in 2022, then surged by 55.35% to -$93.5 million in 2023, then surged by 56.02% to -$41.1 million in 2024, then rose by 4.96% to -$39.1 million in 2025, then surged by 1985.95% to $736.8 million in 2026.
• Business Quant data shows ASND's Profit After Tax at $736.8 million in Q1 2026, -$39.1 million in Q4 2025, and -$71.3 million in Q3 2025.